Cardio-TriTest vs Tempus ECG-AF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Cardio-TriTest is a multi-modal diagnostic device offering comprehensive cardiovascular disease detection through synchronized ECG, PCG, and MCG analysis. In contrast, Tempus ECG-AF is a software-based AI algorithm specifically designed to assess the 12-month risk of new-onset atrial fibrillation in patients aged 65 or older. While both leverage AI in cardiology and utilize ECG data, their distinct focus areas—broad diagnostic screening versus specific arrhythmia risk prediction—make them adjacent rather than direct competitors.
Choose Cardio-TriTest if…
Choose Cardio-TriTest if your primary care clinic requires a comprehensive, multi-modal diagnostic device for earlier and more thorough cardiovascular disease detection. This device is ideal for synchronously acquiring and visually correlating ECG, PCG, and MCG bio-signals, offering a broader diagnostic picture beyond a standard ECG. It's best suited for general practitioners seeking an all-in-one, non-invasive tool to screen for various heart conditions directly in a clinical setting.
View Cardio-TriTest →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your cardiology department or internal medicine practice needs to specifically identify older patients at increased risk of developing new-onset atrial fibrillation within the next year. This AI-based software solution seamlessly integrates with existing 12-lead ECG systems to provide targeted risk stratification for patients aged 65 or older without pre-existing AF. It is particularly useful for proactive management and follow-up in an at-risk geriatric population, leveraging existing infrastructure.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cardio-TriTest | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | On-premise (device) | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Unknown | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cardio-TriTest | Tempus ECG-AF |
|---|---|---|
| Product Name | Cardio-TriTest | Tempus ECG-AF |
| Company | Cardio-Phoenix Inc. | Tempus AI, Inc. |
| Primary Function | AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care. | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Core Diagnostic Modalities | 3-in-1 diagnostic device (ECG, PCG, MCG); 12-Lead Electrocardiograph (ECG); 4 Lead Phonocardiograph (PCG); 4 Lead Mechanocardiograph (MCG); Synchronized bio-signal acquisition; Visual correlation of heart bio-signals; AI-powered analysis. | AI-based algorithm for 12-lead ECG analysis; Trained on over 1.5 million ECGs from over 500,000 patients. |
| Target Condition/Population | Earlier and more comprehensive cardiovascular disease detection. | Patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cardio-TriTest and Tempus ECG-AF.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Cardio-TriTest is a device offering a 3-in-1 diagnostic for earlier, comprehensive cardiovascular disease detection in primary care, requiring direct patient interaction with the device. Tempus ECG-AF is a software algorithm that analyzes existing 12-lead ECGs to identify AF risk in patients 65+, fitting into a workflow where ECGs are already performed and can be uploaded for analysis.
Tempus ECG-AF is designed to integrate with existing ECG platforms and EHRs to enable advanced AI deployment and insights within clinical workflows, and it integrates with healthcare facility systems. For Cardio-TriTest, as a device-based solution, integration would likely involve exporting data from the device for input into the EHR, as its primary function is synchronized bio-signal acquisition and visual correlation.
Cardio-TriTest provides a 3-in-1 diagnostic combining ECG, PCG, and MCG for earlier and more comprehensive cardiovascular disease detection. Tempus ECG-AF specifically identifies patients 65 or older at increased risk of new-onset AF within 12 months, with its algorithm trained on over 1.5 million ECGs from over 500,000 patients and a reported specificity of 92% for classifying patients who did not develop AF.
Cardio-TriTest's 3-in-1 comprehensive approach for earlier and more comprehensive cardiovascular disease detection makes it suitable for Family Medicine. Tempus ECG-AF's focus on identifying AF risk in patients aged 65 or older without pre-existing AF aligns well with the specific needs of Geriatrics for proactive screening and follow-up.
Operating Cardio-TriTest, a physical 3-in-1 diagnostic device, would involve training on its specific acquisition, synchronization, and visual correlation features. Tempus ECG-AF, being a software algorithm, primarily requires staff to understand how to submit compatible ECGs for analysis and interpret the binary risk stratification results in conjunction with other clinical information.
Deploying Cardio-TriTest would involve procuring and installing physical devices at each site, along with staff training for device operation. Tempus ECG-AF, as a software solution integrated into existing systems, would likely involve software deployment and integration across sites, potentially leveraging existing compatible ECG infrastructure.
A physician might choose Cardio-TriTest for a broader, earlier, and more comprehensive cardiovascular screening in primary care settings, aiding in a more complete diagnosis. Conversely, Tempus ECG-AF would be preferred for targeted screening of asymptomatic patients aged 65 or older to identify those at increased risk of developing new-onset atrial fibrillation within the next year, supporting earlier identification and follow-up.
More Comparisons
More matchups featuring Cardio-TriTest or Tempus ECG-AF
Backers
Who funded each tool's parent company.